A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Atorvastatin 20 mg & Pioglitazone 30 mg Tablets Vs Atorvastatin Tablets 20 mg in Patients with Hypercholesteremia.
- Conditions
- Health Condition 1: null- HypercholesteremiaHealth Condition 2: E780- Pure hypercholesterolemia
- Registration Number
- CTRI/2010/091/000431
- Lead Sponsor
- Ajanta Pharma Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
1. Availability of subjects for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent
2. Patient with LDL-cholesterol >= 145 mg/dl (3.75mmol/l) and <= 250 mg/dl (6.47mmol/l) and triglyceride <= 350 mg/dl 93.99 mmol/l)
1. History of hypersensitivity to the study drug or similar class of drug.
2. Significant history or presence of gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of common medications.
3. Pregnant or lactating women.
4. Patients with serum creatinine greater than 2.5 mg/dl.
5. Patients with raised SGPT and total bilirubin greater than 50% above the upper normal limits
6. History of drug dependency, alcohol abuse, or serious neurological or psychological disease.
7. Participation in a clinical trial with an investigation drug within 30 days proceeding day one of this study.
8. Use of enzyme-modifying drugs within 30 days prior to day 1 of this study.
9. HIV and Australian Antigen positive subjects.
10. Any condition that, in the opinion of the investigator, does not justify the patient?s inclusion in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method